Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

 Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Shots:

  • The approval is based on P-III CAIN457A2318 study results assessing Cosentyx (300/150 mg, q4w) vs PBO in 543 patients with moderate-to-severe plaque PsO. Additionally, P-III study in China assessed Cosentyx (300mg, q4w) in 10 Psoriasis patients
  • P-III CAIN457A2318 study results: @12 wks. PASI 75/90 (97.7%, 87.8%/ 80.9%, 66.4%); @16wks. PASI 90 87.0%, well tolerated with both doses; no new safety signals observed: P-III results @12wks. 80% achieved clear or almost clear skin & @16 wks. 87.0% achieved
  • Cosentyx (secukinumab) is a novel biologic that inhibits interleukin-17A (IL-17A) targeted for psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)

Click here to read full press release/ article | Ref: Novartis | Image:

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post